Continuing chemotherapy beyond 6 cycles increases the chances of complete cytoreduction surgery in patients with advanced ovarian cancer
European Journal of Surgical Oncology · 2025
DOI: 10.1016/j.ejso.2025.110288 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Anna Myriam Perrone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Division of Oncologic Gynecology, IRCCS Azienda Ospedalie…. Hauptthemen laut MEDLINE: Cytoreduction Surgical Procedures, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Ministero della Salute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: To evaluate the impact of receiving more than 6 cycles of NACT on survival outcomes and chemotherapy-related toxicity in patients with advanced epithelial ovarian cancer (AOEC) ineligible for primary debulking surgery. METHODS: This retrospective, monocentric, observational study analyzed AEOC patients who received at least 6 cycles of NACT followed by IDS. They were grouped by number of NACT cycles (6 vs ≥ 7) and cytoreduction rate (CC0 vs CC ≥ 1), with a non-surgical group for comparison. RESULTS: A total of 335 patients were evaluated over a 20-year period. Pre-surgical variables were similar across groups, except for older age (p < 0.001) and higher Peritoneal Cancer Index (PCI) (p = 0.04) in the non-surgery cohort. Chemotherapy-related toxicities led to delays in subsequent NACT cycles, mainly in the non-surgery group (p = 0.02). After a median follow-up of 67.7 months, patients with CC0 demonstrated the longest median progression-free survival (PFS): 22 months (NACT=6) vs 21 months (NACT≥7). In CC ≥ 1 patients, PFS was 15 months (NACT=6) and 19 months (NACT≥7), while the non-surgery group had 10 months. CC0 was the primary predictor of overall survival (OS). Patients with CC0-NACT=6 had a median OS of 59 months, compared to 40 months for CC0-NACT≥7 group (p = 0.4), while patients with CC≥1, both NACT=6 and NACT≥7 presented a median OS of 27 months. Achieving CC0 after NACT≥7 significantly improved survival compared to NACT=6-CC≥1 (HR = 1.71, p = 0.019 for PFS; HR = 2.1, p = 0.009 for OS). CONCLUSIONS: Extending NACT beyond 6 cycles may benefit selected patients by enhancing cytoreduction rates and survival without increasing toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Electronic address: lucia…
- Department of Morpho-functional sciences, University of Medicine and Pharmacy "Iuliu Hațieganu", Cluj-Napoca, Romania.
- Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Förderung
- Ministero della Salute
Zitieren
APA
Perrone, A. M., Mezzapesa, F., Genovesi, L., Coada, C. A., Masina, E., Bilancia, E. P., Rubino, D., Zamagni, C., & De Iaco, P. (2025). Continuing chemotherapy beyond 6 cycles increases the chances of complete cytoreduction surgery in patients with advanced ovarian cancer. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.110288
Vancouver
Perrone AM, Mezzapesa F, Genovesi L, Coada CA, Masina E, Bilancia EP, et al. Continuing chemotherapy beyond 6 cycles increases the chances of complete cytoreduction surgery in patients with advanced ovarian cancer. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.110288
BibTeX
@article{Perrone2025,
author = {Perrone, Anna Myriam and Mezzapesa, Francesco and Genovesi, Lucia and Coada, Camelia Alexandra and Masina, Elena and Bilancia, Elisabetta Pia and Rubino, Daniela and Zamagni, Claudio and De Iaco, Pierandrea},
title = {Continuing chemotherapy beyond 6 cycles increases the chances of complete cytoreduction surgery in patients with advanced ovarian cancer},
journal = {European Journal of Surgical Oncology},
year = {2025},
doi = {10.1016/j.ejso.2025.110288}
}
EUVIMED